T. Rowe Price Associates’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

T. Rowe Price Associates’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-36,531	Closed	-$244K	–	2939
2023 Q3	$244K	Buy	36,531 +9,558	+35%	+$79.4K	﹤0.01%	2424
2023 Q2	$245K	Sell	26,973 -9,820	-27%	-$86.6K	﹤0.01%	2456
2023 Q1	$268K	Sell	36,793 -2,262	-6%	-$16.8K	﹤0.01%	2401
2022 Q4	$285K	Sell	39,055 -10,920	-22%	-$81K	﹤0.01%	2390
2022 Q3	$387K	Buy	+49,975	New	+$424K	﹤0.01%	2258
2021 Q1	–	Sell	-921,822	Closed	-$12.9M	–	2881
2020 Q4	$12.9M	Hold	921,822	–	–	﹤0.01%	1317
2020 Q3	$13.3M	Buy	+921,822	New	+$12.6M	﹤0.01%	1232

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

T. Rowe Price Associates's PNT Position: Q4 2023 in Review

T. Rowe Price Associates sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 36,531 shares — an estimated $244K sold.

T. Rowe Price Associates first reported a position in PNT in Q3 2020 and held it in 7 quarters. The position peaked at $13.3M in Q3 2020. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

T. Rowe Price Associates reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
T. Rowe Price Associates sold 36,531 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $244K.
T. Rowe Price Associates first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2020 and held it in 7 quarters.
T. Rowe Price Associates's POINT Biopharma Global Inc. Common Stock position peaked at $13.3M in Q3 2020.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.